Time-dependent risk and predictors of venous thromboembolism in breast cancer patients: A population-based cohort study

被引:33
作者
Brand, Judith S. [1 ]
Hedayati, Elham [2 ]
Bhoo-Pathy, Nirmala [3 ]
Bergh, Jonas [2 ]
Hall, Per [1 ]
Humphreys, Keith [1 ]
Ludvigsson, Jonas F. [1 ]
Czene, Kamila [1 ]
机构
[1] Karolinska Inst, Dept Med Epidemiol & Biostat, Nobels Vag 12A, S-17177 Stockholm, Sweden
[2] Karolinska Univ Hosp, Dept Oncol Pathol, Stockholm, Sweden
[3] Univ Malaya, Fac Med, Kuala Lumpur, Malaysia
基金
瑞典研究理事会;
关键词
breast cancer; epidemiology; predictors; time-dependent risk modeling; venous thromboembolism; ADJUVANT ENDOCRINE THERAPY; BLEEDING COMPLICATIONS; TUMOR CHARACTERISTICS; CHEMOTHERAPY; THROMBOSIS; VALIDATION; TAMOXIFEN; IMPACT; WOMEN; HOSPITALIZATION;
D O I
10.1002/cncr.30364
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUNDVenous thromboembolism (VTE) is a serious complication of cancer and its treatment. The current study assessed the risk and clinical predictors of VTE in breast cancer patients by time since diagnosis. METHODSThis Swedish population-based study included 8338 breast cancer patients diagnosed from 2001 to 2008 in the Stockholm-Gotland region with complete follow-up until 2012. Their incidence of VTE was compared with the incidence among 39,013 age-matched reference individuals from the general population. Cox and flexible parametric models were used to examine associations with patient, tumor, and treatment characteristics, accounting for time-dependent effects. RESULTSOver a median follow-up of 7.2 years, 426 breast cancer patients experienced a VTE event (cumulative incidence, 5.1%). The VTE incidence was 3-fold increased (hazard ratio [HR], 3.28; 95% confidence interval [CI], 2.87-3.74) in comparison with the incidence in the general population and was highest 6 months after diagnosis (HR, 8.62; 95% CI, 6.56-11.33) with a sustained increase in risk thereafter (HR at 5 years, 2.19; 95% CI, 1.80-2.67). Independent predictors of VTE included the following: older age, being overweight, preexisting VTE, comorbid disease, tumor size>40mm, progesterone receptor (PR)-negative status, more than 4 affected lymph nodes, and receipt of chemo- and endocrine therapy. The impact of chemotherapy was limited to early-onset VTE, whereas comorbid disease and PR-negative status were more strongly associated with late-onset events. CONCLUSIONSThis study confirms the long-term risk of VTE in breast cancer patients and identifies a comprehensive set of clinical risk predictors. Temporal associations with patient, tumor, and treatment characteristics provide insight into the time-dependent etiology of VTE. Cancer 2017;123:468-475. (c) 2016 American Cancer Society. Breast cancer patients are at highest risk for venous thromboembolism within the first year of their diagnosis, but the risk remains 2-fold increased for many years afterward. Temporal associations with patient, tumor, and treatment characteristics provide insight into the time-dependent etiology of venous thromboembolism in breast cancer patients.
引用
收藏
页码:468 / 475
页数:8
相关论文
共 41 条
[1]   Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer [J].
Agnelli, Giancarlo ;
George, Daniel J. ;
Kakkar, Ajay K. ;
Fisher, William ;
Lassen, Michael R. ;
Mismetti, Patrick ;
Mouret, Patrick ;
Chaudhari, Umesh ;
Lawson, Francesca ;
Turpie, Alexander G. G. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (07) :601-609
[2]   Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study [J].
Agnelli, Giancarlo ;
Gussoni, Gualberto ;
Bianchini, Carlo ;
Verso, Melina ;
Mandala, Mario ;
Cavanna, Luigi ;
Barni, Sandra ;
Labianca, Roberto ;
Buzzi, Franco ;
Scambia, Giovanni ;
Passalacqua, Rodolfo ;
Ricci, Sergio ;
Gasparini, Giampietro ;
Lorusso, Vito ;
Bonizzoni, Erminio ;
Tonato, Maurizio .
LANCET ONCOLOGY, 2009, 10 (10) :943-949
[3]   Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis [J].
Amir, Eitan ;
Seruga, Bostjan ;
Niraula, Saroj ;
Carlsson, Lindsay ;
Ocana, Alberto .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (17) :1299-1309
[4]   Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance [J].
Arpino, G ;
Weiss, H ;
Lee, AV ;
Schiff, R ;
De Placido, S ;
Osborne, CK ;
Elledge, RM .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (17) :1254-1261
[5]   Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases [J].
Bardou, VJ ;
Arpino, G ;
Elledge, RM ;
Osborne, CK ;
Clark, GM .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (10) :1973-1979
[6]   Venous Thromboembolism A Public Health Concern [J].
Beckman, Michele G. ;
Hooper, W. Craig ;
Critchley, Sara E. ;
Ortel, Thomas L. .
AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2010, 38 (04) :S495-S501
[7]   Incidence of venous thrombosis in a large cohort of 66 329 cancer patients:: results of a record linkage study [J].
Blom, JW ;
Vanderschoot, JPM ;
Oostindiër, MJ ;
Osanto, S ;
van der Meer, FJM ;
Rosendaal, FR .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (03) :529-535
[8]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[9]   Incidence of venous thromboembolism and the impact on survival in breast cancer patients [J].
Chew, Helen K. ;
Wun, Theodore ;
Harvey, Danielle J. ;
Zhou, Hong ;
White, Richard H. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (01) :70-76
[10]   THROMBOEMBOLIC COMPLICATIONS AFTER PERIOPERATIVE CHEMOTHERAPY IN WOMEN WITH EARLY BREAST-CANCER - A EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER BREAST-CANCER COOPERATIVE GROUP-STUDY [J].
CLAHSEN, PC ;
VANDEVELDE, CJH ;
JULIEN, JP ;
FLOIRAS, JL ;
MIGNOLET, FY .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (06) :1266-1271